Asarina Pharma AB (publ) Interim Report, Q1 2019 released

(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management - leading to a solid cash position at the end of the First Quarter.”

Financial Highlights

The company maintained a strict management of its costs. The total cash position at the end of the Quarter was SEK 128.9 million.

The Quarter in Brief

PMDD: Our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD) made good progress, with a drop-out rate of less than 15% compared to more than 30% average in other late stage clinical PMDD studies. We expect topline results in early 2020.

MENSTRUAL MIGRAINE: Our Phase IIa proof-of-concept study in Menstrual Migraine (MM) is on schedule to start enrolment of patients in July. A CTA has been submitted in Sweden and CTAs will be submitted in Denmark and Finland shortly.

AUTOINJECTORS: We are focusing on identifying the best possible autoinjector to administer Sepranolone in future studies and expect to select the final autoinjector for Phase III studies and commercialization in June.

TOURETTE SYNDROME: We published exciting data on Tourette syndrome in March. The data indicate that Sepranolone reduces tics in an animal model of Tourette syndrome on a par with Haldol, the current first-line treatment, without inducing any motor side effects.

For further information see the attached, plus please visit www.asarinapharma.com

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Phone: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: certifiedadviser@penser.se

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAAModulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.

The information above was provided by Asarina Pharma AB (publ) through the above contact person, for publication on May 20, 08.00, 2019.

Tags: